Mycophenolate mofetil can be used as monotherapy late after liver transplantation.
Moreno Planas, Jose Maria; Cuervas-Mons Martinez, Valentin; Rubio Gonzalez, Eduardo; Gomez Cruz, Amparo; Lopez-Monclus, Javier; Sánchez-Turrion, Victor; Lucena Poza, Jose Luis; Jimenez Garrido, Manuel; Millan, Isabel.
Am J Transplant
; 4(10): 1650-5, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15367220
Mycophenolate mofetil versus methotrexate for prevention of graft-versus-host disease in people receiving allogeneic hematopoietic stem cell transplantation.
Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients.
Efficacy and safety of everolimus plus low-dose calcineurin inhibitor vs. mycophenolate mofetil plus standard-dose calcineurin inhibitor in renal transplant recipients: A systematic review and meta-analysisâ©.
Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function.
Relationship between pharmacokinetics and pharmacodynamics of calcineurin inhibitors in renal transplant patients.
Calcineurin inhibitor sparing with mycophenolate mofetil in liver transplantion: a systematic review of randomized controlled trials.
Calcineurin inhibitors in liver transplantation - still champions or threatened by serious competitors?
Current State of Immunosuppression: Past, Present, and Future.
Effect of steroid-free low concentration calcineurin inhibitor maintenance immunosuppression regimen on renal allograft histopathology and function.
Renal-sparing regimens employing new agents.